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Abstract: Head and neck squamous cell carcinoma (HNSCC) is a solid tumor composed by a
genotypically and phenotypically heterogeneous population of neoplastic cells types. High recurrence
rate and regional metastases lead to major morbidity and mortality. Recently, many studies have
focused on cellular and molecular mechanisms of tumor progression that can help to predict
prognosis and to choose the best therapeutic approach for HNSCC patients. Hyaluronan (HA),
an important glycosaminoglycan component of the extracellular matrix (ECM), and its major
cell surface receptor, CD44, have been suggested to be important cellular mediators influencing
tumor progression and treatment resistance in head and neck cancer. HNSCC contains a small
subpopulation of cells that exhibit a hallmark of CD44-expressing cancer stem cell (CSC) properties
with self-renewal, multipotency, and a unique potential for tumor initiation. HA has been shown
to stimulate a variety of CSC functions including self-renewal, clone formation and differentiation.
This review article will present current evidence for the existence of a unique small population
of CD44v3highALDHhigh-expressing CSCs in HNSCC. A special focus will be placed on the role
of HA/CD44-induced oncogenic signaling and histone methyltransferase, DOT1L activities in
regulating histone modifications (via epigenetic changes) and miRNA activation. Many of these
events are essential for the CSC properties such as Nanog/Oct4/Sox2 expression, spheroid/clone
formation, self-renewal, tumor cell migration/invasion, survival and chemotherapeutic drug
resistance in HA-activated head and neck cancer. These newly-discovered HA/CD44-mediated
oncogenic signaling pathways delineate unique tumor dynamics with implications for defining the
drivers of HNSCC progression processes. Most importantly, the important knowledge obtained
from HA/CD44-regulated CSC signaling and functional activation could provide new information
regarding the design of novel drug targets to overcome current therapeutic drug resistance which
will have significant treatment implications for head and neck cancer patients.
Keywords: cancer stem cells (CSCs); hyaluronan (HA); CD44; miR-10b; DOT1L; epigenetic regulation;
HNSCC
1. Hyaluronan (HA) Metabolism in Head and Neck Cancer Progression
Head and Neck Squamous cell carcinoma (HNSCC) is an aggressive malignant neoplasm
associated with major morbidity and mortality. The three-year survival rate for patients with
advanced-stage HNSCC who are treated with standard therapy is only 30% to 50% [1–4]. Resistance
to standard therapy continues to be a limiting factor in the treatment of HNSCC. Nearly 40% to 60%
of patients with HNSCC subsequently develop locoregional recurrences or distant metastases [1–4].
Int. J. Mol. Sci. 2017, 18, 1849; doi:10.3390/ijms18091849 www.mdpi.com/journal/ijms
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Presently, very little information is available regarding the cellular and molecular mechanisms involved
in regulating HNSCC cell signaling and chemotherapeutic responses.
Hyaluronan (HA), one of the major extracellular matrix (ECM) components, is known to contain
repeating disaccharides units, D-glucuronic acid and N-acetyl-D-glucosamine (Figure 1) [5,6]. It is often
accumulated at tumor cell–matrix attachment sites and is closely associated with tumorigenesis and
metastasis [5,6]. HA synthesis or production is regulated by at least three mammalian HA synthase
isozymes including HAS1 (HA synthase 1), HAS2 (HA synthase 2) and HAS3 (HA synthase 3) [7–10].
All three HAS genes are located on different chromosomes. Structurally, all three HAS isozymes appear
to share a great deal of sequence homology [11–13]. Both HAS1 and HAS2 synthesize large-size of HA
(~1 × 106–1 × 107 Da) [11,12] which are known to be important for cell proliferation, angiogenesis and
development [13]. HAS3 synthesizes small-size HA (~1 × 105 Da) [11,12] which appears to contribute
to many malignant behaviors of many different cell types [11,12]. HAS2 has been shown to express in
head and neck cell lines [14]. Downregulation of HAS2 expression resulted in an inhibition of tumor
cell growth and migration as well as an enhancement of cisplatin sensitivity, suggesting the importance
of tumor cell HA production to promote in vitro tumor progression behaviors in oral cancer cells [14].
Overexpression of HAS2 in oral cavity carcinoma clinical specimens was also correlated with poor
clinicopathologic characteristics and worse disease-free survival [14]. These observations strongly
support the contention that HAS expression is closely associated with HNSCC progression. Thus,
differential HAS expression/activities and unique HA-size production could selectively influence
oncogenic signaling pathways and malignant properties leading to tumor progression.
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Figure 1. Hyaluronan (HA) structure regulated by HA synthases and hyaluronidases. 
Large-size HA polymers can be digested or degraded into smaller-sized HA fragments by acid-
active hyaluronidases [15] (Figure 1). Overexpression of hyaluronidases has been associated with 
solid tumor metastases [16]. Presently, at least six hyaluronidase-like gene sequence products (e.g., 
Hyal-1, Hyal-2, Hyal-3, Hyal-4, PHYAL-1, and PH20 (or Spam1)) have been reported [17]. For 
example, the genes of Hyal-1 and Hyal-2 (the major hyaluronidases in human somatic tissues) are 
detected as tight clusters on chromosome 3p21.3. Hyal-1 is enriched in head and neck cancer [18]. 
Hyal-2 initially cleaves high-molecular-weight (HMW) large-size HA into ~20 kDa fragments, which 
are further digested into smaller size fragments by Hyal-1 [19,20]. Interestingly, low-molecular-
weight (LMW) HA or small HA fragments, rather than high-molecular-weight (HMW) large HA, 
have been suggested to be essential for cancer progression in terms of invasion and metastasis [21]. 
Hyal-3 expression is detected in fibroblasts when they are undergone chondrocyte differentiation 
[17,22]. Hyal-4 could be a chondroitinase and PHYAL-1, a pseudogene appears to be untranslated in 
humans [23]. PH20 (or Spam1) belongs to a neutral-active hyaluronidase and is detected primarily in 
Figure 1. Hyaluronan (HA) structure regulated by HA synthases and hyaluronidases.
Large-size HA polymers can be digested or degraded into smaller-sized HA fragments by
acid-active hyaluronidases [15] (Figure 1). Overexpression of hyaluronidases has been associated with
solid tumor metastases [16]. Presently, at least six hyaluronidase-like gene sequence products (e.g.,
Hyal-1, Hyal-2, Hyal-3, Hyal-4, PHYAL-1, and PH20 (or Spam1)) have been reported [17]. For example,
the genes of Hyal-1 and Hyal-2 (the major hyaluronidases in human somatic tissues) are detected as
tight clusters on chromosome 3p21.3. Hyal-1 is enriched in head and neck cancer [18]. Hyal-2 initially
cleaves high-molecular-weight (HMW) large-size HA into ~20 kDa fragments, which are further
digested into smaller size fragments by Hyal-1 [19,20]. Interestingly, low-molecular-weight (LMW) HA
or small HA fragments, rather than high-molecular-weight (HMW) large HA, have been suggested
to be essential for cancer progression in terms of invasion and metastasis [21]. Hyal-3 expression is
detected in fibroblasts when they are undergone chondrocyte differentiation [17,22]. Hyal-4 could
be a chondroitinase and PHYAL-1, a pseudogene appears to be untranslated in humans [23]. PH20
(or Spam1) belongs to a neutral-active hyaluronidase and is detected primarily in testes and in a
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variety of cancers including HNSCC tumors [18,24,25]. Most importantly, the unique HA-enriched
microenvironment appears to serve as a stem cell niche and participates in cellular signaling and a
variety of normal and cancer stem cell CSC)-specific functions [26,27].
2. CD44 (a HA Receptor) in Cancer Stem Cells (CSCs) and Tumor Progression
CD44, a family of transmembrane glycoproteins is expressed in a variety of cells and tissues
including head and neck cells and HNSCC tissues [28–31]. The presence of high levels of CD44 variant
(CD44v) isoforms is emerging as an important metastatic tumor marker in many cancers including
head and neck cancer [28–31]. CD44 gene is known to undergo alternative splicing mechanisms and
produces a variety of CD44 isoforms including CD44s, CD44v3, CD44v6, etc. [32,33] (Figure 2A).
Mack and Gires showed that both CD44s and CD44v6 can be detected in 60–95% and 50–80%,
respectively, of normal epithelia, whereas, in moderately differentiated carcinoma, the level of CD44s
and CD44v6 only increase slightly [34]. Since CD44s and CD44v6 fail to distinguish normal from
benign or malignant epithelia, these two CD44 isoforms cannot be used as reliable tumor markers
for monitoring HNSCC progression. In contrast, CD44v3 can be detected in lymph metastasis and is
closely involved in promoting metastasis and head and neck cancer progression [28–31]. The v3 exon
(but not other variants) product of the CD44 molecule is unique, being the only exon that has a heparin
sulfate (HS) assembly site (33). These v3 exon-containing variants carrying HS side chains bind and
present heparin-binding growth factors and cytokines, such as FGF and heparin-binding epidermal
growth factor (EGF), which may generate various functional consequences. These findings suggest
that different CD44 isoforms may participate in distinct biological activities.
It has been well documented that all CD44 isoforms contain HA-binding domain located at
the N-terminal region of the extracellular domain [35] (Figure 2A). The binding of CD44 isoforms to
hyaluronan affects cell adhesion to extracellular matrix components and is implicated in the stimulation
of aggregation, proliferation, migration, and angiogenesis [28–31,36]. The intracellular domain of CD44
isoforms (e.g., CD44v3) selectively interacts with cytoplasmic regulators (e.g., oncogenic molecules
and cytoskeletal proteins) and effectively transmits cellular signaling [28–31,37–40]. Therefore, CD44
isoforms likely provide a close linkage between matrix components (HA) and cytoplasmic regulators
(Figure 2B). Recent studies have shown that CD44 is also detected in tumor stem cells which have the
unique ability to initiate tumor cell-specific properties [41]. In fact, CD44 is proposed to be one of the
important surface markers for cancer stem cells [41]. Both CD44v isoforms and HA are overexpressed
at sites of tumor attachment [42].
Accumulating evidence indicates that most tumors contain special subpopulations of cells, which
appear to be highly tumorigenic and are involved in tumor progression. These “Cancer Stem Cells
(CSCs)” or “Tumor-Initiating Cells (TICs)” share several common properties of normal stem cells [43,44].
However, some CSCs have altered their ability to regulate normal stem cell numbers, pluripotency, and
lineage-dependent differentiation [43,44]. CSCs frequently undergo cell division/growth and/or
clone formation and differentiation to expand the stem cell population [43,44]. They are also
capable of generating self-renewal, maintaining quiescence, and displaying multipotentiality [43,44].
Consequently, CSC-derived tumor cells often display a variety of properties which are different from
the parental tumor cells. These studies suggest that tumor formation could be a result of a variety of
CSCS signaling modifications and/or functional alterations. Furthermore, CSCs have been shown to
be chemoresistant and are possibly responsible for cancer relapse.
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detected by injecti g as few as ~50 CD44v3highALDH1high cells (but not CD44v3lowALDH11ow cells or
unsorted cells) into NOD/SCID mice [48–50]. These findings suggest that the high level of tumorigenic
effect induced by CD44v3highALDH1high cells (but not CD44v3lowALDH11ow cells or uns rted cells)
may be caused by unique t mor initiation properties of these sub opulations of HNSCC cells [48].
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3. Hyaluronan–CD44 Interaction Stimulates Stem Cell Marker Expression, Stemness Properties
and Chemoresistance in CD44v3highALDH1high Head and Neck Cancer Stem Cells (CSCs)
One of the common properties of CD44v3highALDH1high CSCs isolated from HNSCC is the
upregulation of cancer stem cell markers (e.g., Nanog, Sox2 and Oct4) which are known to function
as transcriptional factors [48–50]. These three regulatory factors often form a combinational
complex to stimulate specific genes targeting for the expression of stem cell properties including
proliferation, self-renewal, and differentiation [51]. Overexpression of Nanog/Sox2/Oct4 has also
been closely correlated with higher histological grades and poorer clinical survival in head and
neck cancer [48,52–56]. Nanog is an important transcription factor that renders the reprogramming
adult stems into germ-line-competent induced pluripotent stem (iPS) cells [57]. It is expressed not
only in germ cell tumors, but also in many other tumors including HNSCC cells and tissues [48,53].
In HNSCC, high expression of Nanog has been shown to be associated with advanced cancer stages
and HNSCC progression [48,53,55,56]. Sox2 (Sex determining region Y-box (2)) is known to be
involved in the maintenance of embryonic stem cell pluripotency and in multiple developmental
processes [53,58–60]. Due to the weak DNA binding ability, Sox2 often forms complexes with other
transcription factors [58]. Increasing numbers of studies regarding the association between SOX2 and
malignant tumors (e.g., head and neck cancer) have been reported [59,60]. Overexpression of SOX2 is
associated with lymph node metastasis in oral cancer [54]. Another stem cell marker, Oct4 is known to
act as an important transcriptional factor which binds to an octameric sequence motif containing the
AGTCAAAT consensus sequence to cause both the onset and maintenance of pluripotency during
embryonic development [61]. Oct4 also interacts with other stem cell markers, such as Nanog and
Sox2, by forming a large regulatory complexes or networks that stimulate pluripotency and/or
block differentiation [58,62]. Moreover, stem cell profiling in head and neck cancer reveals an Oct-4
expressing subpopulation with properties of chemoresistance [63]. Most importantly, the expression of
stem cell markers such as Nanog, Sox2 and Oct4 is closely associated with HNSCC patient’s prognosis,
pathological stages, cancer recurrence and therapy resistance [55,56]. Therefore, searching for new
cancer stem cell targets or designing drugs to manipulate the known molecular targets in CSCs could
be useful for improvements in clinical outcomes of the disease.
It has been reported that self-renewal, proliferation and differentiation regulated by
Nanog/Sox2/Oct4 are the hallmark of stem cell properties that allow CSCs to produce both new
cancer stem cells and phenotypically diverse cancer cells with different proliferative potential [43,44].
All three stem cell markers (i.e., Nanog, Oct4 and Sox2) have been shown to be upregulated (Figure 3B)
and can be recruited into the CD44v3-associated membranes during HA-mediated signaling in these
head and neck CSCs [48,49] (Figure 3E). Recent studies also indicate that HA binding to CD44
induces upregulation of Nanog, Sox2 and Oct4 expression and activates a variety of important target
genes such as miR-302 and miR-21 in CD44v3highALDH1high head and neck CSCs and breast tumor
cells, respectively [48,64,65] (Figure 3E). Most importantly, HA-mediated CD44 signaling promotes
spheroid (Figure 3C) and clone formation (Figure 3D), as well as cell growth/self-renewal properties
of CD44v3highALDH1high head and neck CSCs [48,49]. These findings strongly suggest that HA–CD44
interaction is tightly linked to the onset of stem cell marker (Nanog/Sox2/Oct4) expression and the
subsequent stem cell functions in CSCs isolated from HNSCC.
Head and neck cancer treatment commonly involves the use of cisplatin-related chemotherapeutic
drugs. HNSCC tumor resistance to chemotherapy is often caused by the presence of anti-apoptotic
regulators [31,66]. IAP family (e.g., cIAP-1, cIAP-2 and XIAP) appears to play an important role
in suppressing apoptosis and promoting oncogenesis [66]. IAPs not only block the activities of
several caspases and pro-caspases such as caspase-3 and caspase-7 [67], but also prevent anti-cancer
drug-induced tumor cell death [67]. Even though some attention has been paid to the involvement of
other anti-apoptotic proteins (e.g., Bcl-xL) in anti-apoptosis and chemoresistance of breast tumor cells
in the presence of HA [68], recently, there is a significant interest of investigating a possible role of IAPs
in HA-treated HNSCC tumor resistance [69]. Recent results show that there is a significant elevation
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of IAP protein (e.g., cIAP-1, cIAP-2 and XIAP) expression in CD44v3highALDH1high head and neck
CSCs following HA treatment [48–50]. Upon treatment of cisplatin, these CSCs show a reduction
in apoptosis and cell death (possibly due to an increase of IAP production and tumor cell survival)
and a significant increase in cisplatin-resistance [48–50] (Figure 3E). Taken together, these findings
strongly suggest that HA–CD44 interaction plays an important role in promoting Nanog/Oct4/Sox2
upregulation, stemness properties, tumorigenesis and chemoresistance in CD44v3highALDH1high head
and neck CSCs, which are important contributors to HNSCC progression. Another cell surface marker
is the single-chain sialoglycoprotein CD24, which is also associated with cancer stem cell characteristics
in colorectal and pancreatic cancer, while head and neck cancer cells and breast cancer cells with
CD44+CD24−/low expression are highly tumorigenic [70–72]. However, the question of whether HA
displays any effect on CD44+CD24−/low cancer stem cells is presently unknown.
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markers Nanog, Oct4 and Sox2 in CD44v3highALDH1high cells (treated with no HA or with HA) using 
immunoblot analyses. (C) Sphere formation of CD44v3highALDH1high cells in: the absence of HA; or 
the presence of HA. (D) Clone formation of CD44v3highALDH1high cells in: the absence of HA; or the 
presence of HA. (E) A proposed HA-induced CD44v3 signaling in CD44v3highALDH1high cells. The 
binding of HA to CD44v3-expressing CSCs promotes Nanog/Oct4/Sox2 association with CD44v3 first 
followed by Nanog/Oct4/Sox2 translocation to the promoter sites of target genes. Subsequently, 
Nanog/Oct4/Sox2-specific target genes (e.g., miR-302 and miR-21) are expressed leading to stemness 
Figure 3. Characterization of cancer stem cel opulation from tumor-d rived HNSC (HSC-3
cells). (A) Flow cytometry analyses of HS -3 t or cell populations: Specifically, HSC-3 cells were
stained with both allophycocyanin (APC)-labeled anti-CD44v3 antibody (recognizing the v3-specific
domain of CD44) and ALDEFLUOR (measuring an ALDH1 enzymatic activity) followed by processing
through multicolor fluorescence-activated cell sorter (FACS) and cell sorting. (Top right quad
represents CD44v3highALDH1high cells (15%); Top left quad represents CD44v3highALDH1low cells
(7%); Bottom right quad represents CD44v3lowALDH1high cells (2%); and Bottom left quad represents
CD44v3lowALDH1low cells (76%). A FACS-fluorescence-activated cell sorter was then used to isolate
CD44v3highALDH1high cells or CD44v3lowALDH1low ls for the study; (B) detection of stem cell
markers Nanog, Oct4 and Sox2 in CD44v3highALDH1high cells (treated with no HA or with HA) using
immunoblot analyses. (C) Sph re formati n of CD44v3highALDH1high cells i : the absence of HA;
or the presence of HA. (D) Clone formation of CD44v3highALDH1high cells in: the absence of HA;
or the presence of HA. (E) A proposed HA-induced CD44v3 signaling in CD44v3highALDH1high cells.
The binding of HA to CD44v3-expressing CSCs promotes Nanog/Oct4/Sox2 association with CD44v3
first followed by Nanog/Oct4/Sox2 translocation to the promoter sites of target genes. Subsequently,
Nanog/Oct4/Sox2-specific target genes (e.g., miR-302 and miR-21) are expressed leading to stemness
properties (e.g., sphere formation, self-renewal, cell proliferation, survival and chenoresistance) and
tumor progression.
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4. Hyaluronan (HA) Promote miRNA-10b Expression, Tumor Cell Invasion and Chemoresistance
in Head and Neck Cancer Stem Cells (CSCs)
It has been well-documented that cytoskeleton functions are directly involved in tumor cell
invasion of surrounding tissue, and metastasis [73]. During the search for cellular regulators
that are involved in controlling cytoskeleton function and cell migration/invasion in HNSCC,
certain microRNAs (miRNAs) (~22 nucleotides) known to function as RNA interference for gene
regulation [74] were identified. Alterations of miRNAs are often associated with the pathogenesis
of HNSCC [75]. Several previous studies demonstrated that certain oncogenic microRNAs
promote the cell functions of CD44v3highALDH1high (CSC-like) subpopulation isolated from HNSCC
(HSC-3) [48–50]. However, the information regarding the regulation of miRNA production by matrix
component(s) in head and neck cancer CSCs is very limited.
One general concept that has emerged from recent studies is that HA fragments (small vs. mid-size
HAs) and their larger precursor molecules (i.e., intact HA) may be involved in regulating distinct
biological activities including miRNAs [48–50,76,77]. For example, the generation of different sizes
of HA fragments from large/intact HA in the ECM occurs during periods of cell growth, migration,
differentiation and development as well as injury-related repairs [9,10]. Several studies indicate that
there is a selective activation of transcriptional activation and differentiation by large HA fragments,
but not small HA fragments. Other cellular functions such as cell proliferation and migration appear
to be preferentially regulated by small-size HA fragments, but not large-size HA. [49,76,77]. Recently,
a panel of stem cell-related miRNAs including miR-10b, miR-27b, miR-373, miR-181, miR-34a and
miRNA-145 has been shown to be preferentially up-regulated by 200 kDa-HA in head and neck
CSCs [49]. In contrast, the other sizes of HA (e.g., 5 kDa-HA, 20 kDa-HA and 700 kDa-HA) fail to induce
stem cell-specific miRNA production in the CD44v3highALDH1high (CSC-like) subpopulation from
HNSCC cells [49]. Most noticeably, miR-10 has been shown to undergo the highest level of stimulation
by 200 kDa-HA in CSCs isolated from HNSCC [49]. In a previous study, miRNA-10b was found to be
overexpressed in malignant glioma in addition to the overexpression of RhoC and uPAR which are
contributors to glioma invasion and migration [78]. Most importantly, 200 kDa-HA/CD44-activated
miR-10b production also plays an important role in upregulating the cytoskeleton regulator, RhoC
and CSC migration/invasion [49,50]. Treatment of CSCs with an anti-miR-10 inhibitor significantly
decreases RhoC expression and blocks CSC migration/invasion [49,50]. These findings suggest that
miR-10 is closely involved in regulating cytoskeleton function required for CSC migration/invasion
and the miR-10b inhibitor may be considered as a promising new anti-cancer agent.
Treatment of head and neck cancer CSCs with 200 kDa-HA also causes cisplatin resistance [49].
Survival proteins such as Inhibitors of Apoptosis Proteins (IAPs) are frequently upregulated in CSCs
following HA treatment [48–50]. Importantly, high levels of IAPs in CSCs increase cell survival due to
the binding of IAPs to caspases and the suppression of apoptosis [48–50]. A recent study indicates
that the expression of IAPs such as c-IAP-1 significantly increased in CD44v3highALDH1high head
and neck cancer CSCs treated with 200 kDa-HA [49]. There is only a relatively low level of c-IAP-1
expression detected with other sizes of HAs (e.g., 5 kDa-HA, 20 kDa-HA or no HA treatment) [49].
These findings clearly indicate that the survival proteins such as c-IAP-1 is up-regulated in the CSC
subpopulation isolated from HNSCC cells following 200 kDa-HA treatment. Further analyses show
that the addition of 200 kDa-HA in CSCs not only significantly increases miR-10b expression, but
also greatly decreases the ability of cisplatin to induce tumor cell death [49]. These observations
strongly suggest that 200 kDa-HA causes both a decrease in tumor cell death and an increase in
tumor cell survival leading to the enhancement of chemoresistance [49]. Moreover, downregulation
of miR-10b using anti-miR-10b inhibitor significantly reduces the survival and increases cisplatin
sensitivity in 200 kDa-treated CSCs [49]. These findings clearly suggest that downregulation of the
200 kDa-HA-induced miR-10 b function (by anti-miR-10 b treatment) may represent a new target for
therapeutic agents designed to cause head and neck cancer CSCs to undergo cell death and remain
chemotherapy sensitive.
Int. J. Mol. Sci. 2017, 18, 1849 8 of 14
5. HA–CD44 Interaction Promotes Histone Methyltransferase, DOT1L Expression and Epigenetic
Modification in Head and Neck Cancer Stem Cells
Epigenetic changes such as histone methylation have emerged as one of the important regulatory
processes in the chromatin structural modifications and the gene expression alterations during cancer
progression [79]. Methylation of histone H3 at lysine 79 (H3K79) is highly conserved among most
eukaryotic species. In budding yeast, nearly 90% of histone H3 displays either monomethylation
(H3K79me1), dimethylation (H3K79me2) or trimethylation (H3K79me3) at lysine 79, all catalyzed
exclusively by the histone methyltransferase, DOT1 [80,81]. In Saccharomyces cerevisiae, DOT1
was initially identified as a disruptor of telomeric silencing. The orthologs of DOT1 appear to
be evolutionarily conserved from yeast to mammals [80,81]. Both DOT1 and the mammalian
DOT1L (DOT1-like protein) function as H3K79 methyltransferases in the regulation of histone
H3K79 methylation and transcriptional activation [82]. Specifically, DOT1/DOT1L-mediated H3K79
methylation is known to be involved in the control of transcriptional activity required for cell
cycle, meiotic checkpoint and the DNA damage checkpoint [83]. An earlier study indicated that
mammalian DOT1L participates in proliferation and differentiation in embryonic stem (ES) cells [84].
It has also been reported that aberrant H3K79 methylation by DOT1L occurs in Mixed Lineage
Leukemia (MLL) [85]. Treatment of MLL-rearranged leukemia with EPZ00477 or EPZ-5676 (potent
and selective amino nucleoside inhibitors of DOT1L histone methyltransferase activity) causes cell
death in acute leukemia lines bearing MLL translocations [86,87]. Furthermore, downregulation of
H3K79 methyltransferase, DOT1L, using specific DOT1LsiRNA also reduced proliferation of lung
cancer cells [88]. These findings indicate that H3K79 methyltransferase, DOT1L, plays an important
role in promoting cancer formation.
A recent study indicates that histone methyltransferase, DOT1L can be upregulated by HA in
CD44v3highALDH1high head and neck CSCs [50]. Previously, tumor invasion and migration-associated
miR-10b has been shown to contain several predicted E-box elements at its upstream promoter
region [89]. DOT1L-activated H3K79 methylation appears to be directly involved in the binding of
the E-box elements at the miR-10b promoter leading to miR-10b gene expression and production
in head and neck cancer CSCs treated with HA [50]. Further analyses indicate that the
stimulation of microRNA-10b (miR-10b) expression is DOT1L-specific and HA/CD44-dependent in
CD44v3highALDH1high CSCs. This process subsequently results in the overexpression of RhoGTPases
and survival proteins leading to tumor cell invasion and cisplatin resistance. These findings
suggest that HA/CD44-activated miR-10 production plays an important role in upregulating the
cytoskeleton regulator, RhoC in CSC-like cells. Most importantly, we found that downregulation
of HA-activated DOT1L signaling or miR-10b production by treating CSCs with DOT1L siRNA or
anti-miR-10b inhibitor, respectively, not only reduces RhoGTPase (RhoC) expression and impairs
tumor cell migration/invasion but also enhances chemosensitivity [50]. These observations clearly
establish a causal link between DOT1L/H3K79 methylation and miR-10b function including
cytoskeleton-regulated CSC invasion and chemoresistance in HA-treated CSCs. Taken together,
these findings strongly support the contention that histone methyltransferase, DOT1L-associated
epigenetic changes induced by HA play pivotal roles in miR-10 production leading to upregulation of
RhoGTPase and survival proteins. These events are critically important for the acquisition of cancer
stem cell properties including tumor cell invasion and chemotherapy resistance in HA/CD44-activated
CD44v3highALDH1high head and neck cancer CSCs (Figure 4).
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Figure 4. A summary for DOT1L-H3K79 methylation signaling in influencing miRNA-10 gene
expression and production as well as Cancer Stem Cell (CSC) functions in HA-treated
CD44v3highALDH1high cells. The binding of HA (Step 1) to CD44v3-expressing CSCs enhances DOT1L
upregulation (Step 2) and DOT1L/H3K79 methylation-mediated epigenetic changes (Step 2), resulting
in methyl-H3K79 binding to miR-10b promoter (Step 3), and miR-10b gene expression/production
(Step 4). The expressed miR-10b then promotes upregulation of RhoC (cytoskeleton activator) and
CSC-mediated invasion (Step 5). Moreover, miR-10b also induces survival protein, IAP (cIAP-1/cIAP-2
and XIAP) expression, HNSCC cell anti-apoptosis/survival and chemoresistance (Step 6). Red dot
represents DOT1L/H3K79-mediated histone modifications (via epigenetic changes). Taken together,
these findings suggest that targeting HA-mediated DOT1L/H3K79 methylation pathways and miR-10b
function may provide a new drug target to sensitize cancer stem cell apoptosis/death and overcome
cisplatin resistance in CSC-derived HNSCC cells.
6. Conclusions
This review has placed a special focus on the properties of a unique subpopulation of
HNSCC cells (i.e., CD44v3highALDH1high), which displays CSC characteristics with high tumorigenic
potential and chemoresistance. These CD44v3highALDH1high-expressing CSCs appear to be closely
involved in the pathobiology of head and neck squamous cell carcinomas. Most importantly,
matrix hyaluronan (HA) interaction with CD44v3 plays a pivotal role in regulating stem cell
marker expression, stemness properties (e.g., spheroid formation, clone formation, self-renewal,
differentiation) and chemoresistance in these head and neck cancer stem cells. Moreover,
histone methyltransferase, DOT1L/H3K79 methylation-associated epigenetic changes induced by
matrix HA has been shown to directly regulate miR-10 production leading to up-regulation
of RhoGTPase and survival proteins as well as migration/invasion and chemoresistance in
CD44v3highALDH1high-expressing CSCs. In the future, cancer stem cell-based signaling perturbation
therapies may be developed to downregulate stem cell transcription factors and/or histone
methyltransferase, DOT1L (using Nanog/Oct4/Sox2/DOT1L-specific siRNA and shRNA vector
approaches or DOT1L inhibitors) and/or to silence miR-10b (using anti-miR-10b inhibitor) for blocking
HA/CD44v3-mediated Nanog/Oct4/Sox2 signaling and DOT1L/miR-10b expression/function as
well as chemoresistance and HNSCC progression. Taken together, these recently discovered matrix
hyaluronan (HA)/CD44v3-mediated signaling pathways and DOT1L-specific epigenetic regulation in
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head and neck CSCs could provide unique molecular targets and specific therapeutic drugs for the
treatment of head and neck cancer.
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